Find a Research Lab

Enter a research interest, principal investigator or keyword

Displaying 21 to 30 of 129 results for cancer

Show: 10 · 20 · 50

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  • Cullman Chemoprotection Center

    Research in the Cullman Chemoprotection Center focuses on developing nutritional strategies for chronic disease prevention in humans. Our work draws from natural product chemistry, enzymology, nutritional epidemiology and clinical research. A number of our studies look at the glucosinolates and isothiocyanates found in cruciferous vegetables and in Moringa oleifera, also known as the “drumstick tree.” Our team has found that broccoli sprouts are a rich source of the enzyme inducers that detoxify carcinogens and that two of the inducers — sulforaphane in broccoli and isothiocyanate in Moringa oleifera — act as strong antibiotics against Helicobacter pylori, which can cause peptic ulcer disease and stomach cancer.

    Research Areas: nutrition, chemoprotection, cancer, disease prevention, chemistry

  • Cynthia Sears Laboratory

    Work in the Cynthia Sears Laboratory focuses on the bacterial contributions to the development of human colon cancer and the impact of the microbiome on other cancers and the therapy of cancer. The current work involves mouse and human studies to define how enterotoxigenic Bacteroides fragilis, pks+ Escherichia coli, Fusobacterium nucleatum, biofilms and the colonic microbiota induce chronic colonic inflammation and colon cancer. Prospective human studies of the microbiome and biofilms in screening colonoscopy are in progress as are studies to determine if and how the microbiome impacts the response of individuals with cancer to immunotherapy and other cancer therapies.

    Research Areas: epidemiology, AIDS, microbiome, colon cancer, enterotoxigenic Bacteroides fragilis, chronic colonic inflammation

    Principal Investigator

    Cynthia Sears, M.D.

    Department

    Medicine

  • Daria Gaykalova Lab

    The Daria Gakalova Lab defines the functional role of epigenetics in transcriptional regulation of head and neck squamous cell carcinoma (HNSCC) progression. To evaluate the whole-genome distribution of various histone marks, her team is using chromatin immunoprecipitation followed by massively parallel DNA sequencing (ChIP-Seq) for primary tissues, a method recently developed by her lab. The research group of Daria Gaykalova was the first to demonstrate the cancer-specific distribution of H3K4me3 and H3K27ac marks and their role in cancer-related gene expression in HNSCC. The research showed that an aberrant chromatin alteration is a central event in carcinogenesis and that the therapeutic control of chromatin structure can prevent the primary of secondary cancerization. Further preliminary data suggest that the differential enrichment of these disease-specific histone marks and DNA methylation correlate with alternative splicing events (ASE) formation. For this project, Dr. Gaykalova... and her team employed a novel bioinformatical tool for the detection of cancer-specific ASEs. Through thorough functional validation of the individual ASEs, the lab demonstrated that each of them has a unique mechanism of malignant transformation of the cells. Due to high disease specificity, ASEs represent the perfect biomarkers of the neoantigens and have direct application to clinical practice. view less

    Research Areas: Head and neck squamous cell carcinoma, Human papillomavirus, Alternative splicing, epigenetics, Chromatin structure, Cancer genomics, head and neck cancer

  • David Cooper Lab

    Research in the David S. Cooper Lab focuses primarily on hyperthyroidism and thyroid cancer. Topics of recent published studies include the NTCTCS staging systems for differentiated thyroid cancer, radioiodine remnant ablation in low-risk differentiated thyroid cancer, and the link between race/ethnicity and the prevalence of thyrotoxicosis in young Americans.

    Research Areas: neoplasms, hyperthyroidism, cancer, thyroidectomy, thyroid, Graves’ disease, hypothyroidism

    Principal Investigator

    David Cooper, M.D.

    Department

    Medicine

  • Dermot Maher Lab

    Research in the Dermot Maher Lab focuses on cancer pain management. We aim to characterize the immunosuppression that occurs with the use of certain pharmacologic pain therapies, including opioids. We also study the relationship between this pharmacologically induced immunosuppression and the rate of manifestation and recurrence of certain types of malignancies. Our goal is to gain a broader understanding of the benefits and side effects of pain medication pharmacology in order to help patients suffering from painful and complex conditions, such as cancer, manage their symptoms more effectively.

    Research Areas: opioids, pain management, cancer, immunosuppression, pharmacology

  • Devreotes Laboratory

    The Devreotes Laboratory is engaged in genetic analysis of chemotaxis in eukaryotic cells. Our long-term goal is a complete description of the network controlling chemotactic behavior. We are analyzing combinations of deficiencies to understand interactions among network components and carrying out additional genetic screens to identify new pathways involved in chemotaxis. A comprehensive understanding of this fascinating process should lead to control of pathological conditions such as inflammation and cancer metastasis.

    Research Areas: biochemistry, cell biology, chemotaxis, cancer, genomics, inflammation

    Lab Website

    Principal Investigator

    Peter Devreotes, Ph.D.

    Department

    Cell Biology

  • Dmitri Artemov Lab

    The Artemov lab is within the Division of Cancer Imaging Research in the Department of Radiology and Radiological Science. The lab focuses on 1) Use of advanced dynamic contrast enhanced-MRI and activated dual-contrast MRI to perform image-guided combination therapy of triple negative breast cancer and to assess therapeutic response. 2) Development of noninvasive MR markers of cell viability based on a dual-contrast technique that enables simultaneous tracking and monitoring of viability of transplanted stems cells in vivo. 3) Development of Tc-99m and Ga-68 angiogenic SPECT/PET tracers to image expression of VEGF receptors that are involved in tumor angiogenesis and can be important therapeutic targets. 4) Development of the concept of “click therapy” that combines advantages of multi-component targeting, bio-orthogonal conjugation and image guidance and preclinical validation in breast and prostate cancer models.

    Research Areas: VEGF receptors image expression, SPECT/PET tracers, tracking stem cells in vivo, triple-negative breast cancer, image-guided combination therapy, MRI, noninvasive MR markers, cancer imaging

  • Douglas Ball Lab

    The Douglas Ball Lab conducts clinical trials and pre-clinical laboratory studies of thyroid cancer. Our clinical trials, performed in collaboration with research staff in the upper aero-digestive group in the Sidney Kimmel Comprehensive Cancer Center, have included protocols for advanced radioiodine-refractory differentiated thyroid cancer and medullary thyroid cancer. Our pre-clinical research, conducted with Dr. Nelkin, Dr. Agrawal and other Kimmel Cancer Center researchers, includes pathogenesis and mechanisms of treatment resistance in medullary thyroid cancer, and pathogenesis and immune-directed therapy of anaplastic thyroid cancer.

    Research Areas: thyroid cancer, medullary thyroid cancer, cancer, anaplastic thyroid cancer

    Principal Investigator

    Douglas Ball, M.D.

    Department

    Medicine

  • Drew Pardoll Lab

    The Pardoll Lab focuses on the regulation of antigen-specific T cell responses and studies approaches to modify these responses for immunotherapy. Pardoll has a particular interest in cancer immunology and his lab’s studies on basic immunologic mechanisms have led to the development and design of a number of cancer vaccines and discovery of key checkpoint ligands and receptors, such as PD-L2, LAG-3 and neuritin, many of which are being targeted clinically.

    Our primary pursuits are discovering and elucidating new molecules that regulate immune responses, investigating the biology of regulatory T cells, and better understanding the specific biochemical signatures that allow a patient’s T cells to selectively target cancer cells.

    Research Areas: tumor antigens, cancer, immunotherapy, regulatory T cells, T cells

    Principal Investigator

    Drew Pardoll, M.D., Ph.D.

    Department

    Medicine
    Oncology
    Pathology

  • Drug Discovery Group

    Barbara Slusher, M.A.S., Ph.D., leads a 20-member veteran drug discovery team of medicinal chemists, assay developers, pharmacologists, toxicologists and pharmacokinetic/drug metabolism experts, who identify novel drug targets arising from JHU faculty’s research and translate them into new, small molecule drug therapies.

    Her team collaborates extensively with faculty at the Bloomberg~Kimmel Institute for Cancer Immunotherapy and leads the BKI immunotherapy drug discovery core, aimed at developing new immune-targeting drug therapies for laboratory and clinical testing at Johns Hopkins.

    Research Areas: glutamine antagonist, drug discovery, cancer, immunotherapy, cancer metabolism

    Lab Website

    Principal Investigator

    Barbara Slusher, M.A.S., Ph.D.

    Department

    Oncology

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5